| Not Yet Recruiting | A Study to Describe the Safety and Immunogenicity of a Respiratory Syncytial Virus Vaccine IN006 in Healthy Ad NCT06287450 | Shenzhen Shenxin Biotechnology Co., Ltd | Phase 1 |
| Not Yet Recruiting | Evaluating the Benefits of RSV Maternal Vaccination Using a Scottish National Dataset NCT07235397 | Pfizer | — |
| Not Yet Recruiting | Effectiveness of Immunization in Preventing Severe Acute Respiratory Infection RSV NCT07279298 | Bogotá District Health Secretariat | — |
| Recruiting | A Study of S-337395 in Symptomatic Nonhospitalized Adults With Respiratory Syncytial Virus (RSV) Who Are at Hi NCT07214571 | Shionogi | Phase 2 |
| Recruiting | A Study on the Immune Response and Safety of Vaccine Against Respiratory Syncytial Virus Given to Chinese Adul NCT07220109 | GlaxoSmithKline | Phase 3 |
| Recruiting | Genotype and Disease Burden of RSV in Older Vietnamese Adults (RSV: Respiratory Syncytial Virus ) NCT07239583 | Tam Anh Research Institute | — |
| Recruiting | A Study Evaluating Persistence of the Immune Response of the Adjuvanted Respiratory Syncytial Virus (RSV) Vacc NCT07092865 | GlaxoSmithKline | Phase 2 |
| Completed | A Sudy to Evaluate the Efficacy and Safety of TNM001 in High-risk Infants NCT06710925 | Zhuhai Trinomab Pharmaceutical Co., Ltd. | Phase 3 |
| Active Not Recruiting | A Study to Describe the Safety and Immunogenicity of a Respiratory Syncytial Virus Vaccine IN006 in Healthy Ad NCT06645665 | Shenzhen Shenxin Biotechnology Co., Ltd | Phase 1 |
| Recruiting | Study on Safety and Efficacy of Two Doses of PRS CK STORM in the Modulation of the Cytokine Storm for the Trea NCT06684379 | PEACHES BIOTECH | Phase 1 / Phase 2 |
| Completed | A Study in India on the Immune Response and Safety of a Respiratory Syncytial Virus (RSV) Older Adults (OA) Va NCT06614725 | GlaxoSmithKline | Phase 3 |
| Recruiting | RSV Vaccine in Transplant Recipients NCT06593210 | University Health Network, Toronto | Phase 3 |
| Active Not Recruiting | A Study on the Safety and Immune Response to an mRNA-based RSV Investigational Vaccine in Healthy Adults Aged NCT06573281 | GlaxoSmithKline | Phase 1 |
| Completed | A Study on the Immune Response, Safety and the Occurrence of Respiratory Syncytial Virus (RSV)-Associated Resp NCT06551181 | GlaxoSmithKline | Phase 3 |
| Active Not Recruiting | An Extension and Crossover Vaccination Study on the Immune Response and Safety of a Vaccine Against Respirator NCT06534892 | GlaxoSmithKline | Phase 3 |
| Active Not Recruiting | Phase I, First-In Human Study to Evaluate Safety and Tolerability of EuRSV in Healthy Adults Aged Between 19 Y NCT06216093 | EuBiologics Co.,Ltd | Phase 1 |
| Unknown | A Study to Describe the Safety and Immunogenicity of a Respiratory Syncytial Virus Vaccine STR-V003 in Healthy NCT06344975 | Starna Therapeutics | Phase 1 / Phase 2 |
| Completed | A Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus (RSV) When Given Al NCT06374394 | GlaxoSmithKline | Phase 3 |
| Completed | A Study on the Immune Response and Safety of Vaccine Against Respiratory Syncytial Virus (RSV) Given to Adults NCT06389487 | GlaxoSmithKline | Phase 3 |
| Completed | A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Oral Deuremidevir Hydrobromide for Suspe NCT06328400 | Vigonvita Life Sciences | Phase 1 |
| Recruiting | Human Interferon α1b Inhalation Solution Against Respiratory Syncytial Virus in Children With Lower Respirator NCT06363370 | Kexing Biopharm Co., Ltd. | Phase 3 |
| Unknown | A Study to Evaluate the Safety, Immunogenicity, and Pharmacokinetics of GR2102 in Healthy Adult NCT06313697 | Genrix (Shanghai) Biopharmaceutical Co., Ltd. | Phase 1 |
| Terminated | A Study to Learn About the Amount of the Study Medicine (Sisunatovir) in Blood and Its Safety in Infants and C NCT06102174 | Pfizer | Phase 1 |
| Recruiting | Identification and Clinical Validation of Biomarkers Associated With Clinical Severity in Adults Infected With NCT06197152 | Assistance Publique - Hôpitaux de Paris | — |
| Completed | A Trial to Evaluate the Efficacy and Safety of TNM001 for the Prevention of Lower Respiratory Tract Infection NCT06083623 | Zhuhai Trinomab Pharmaceutical Co., Ltd. | Phase 2 / Phase 3 |
| Completed | A Study on Safety and Immune Response of Investigational RSV OA Vaccine in Combination With Herpes Zoster Vacc NCT05966090 | GlaxoSmithKline | Phase 3 |
| Completed | A Study on the Immune Response and Safety of an RSV Vaccine When Given to Adults 18 Years of Age and Above Who NCT05921903 | GlaxoSmithKline | Phase 2 |
| Completed | A Study to Assess Safety, Pharmacokinetics Anti-Drug Antibody and Anti-RSV Antibody After 2 Doses of Nirsevima NCT06042049 | AstraZeneca | Phase 3 |
| Completed | A Study of AK0529 in Adults Patients Hospitalized With RSV Infection NCT06942299 | Shanghai Ark Biopharmaceutical Co., Ltd. | Phase 2 |
| Completed | Prospective Surveillance of Respiratory Syncytial Virus Disease in Infants and Toddlers NCT05964582 | Sanofi Pasteur, a Sanofi Company | — |
| Completed | Infection Watch Study NCT04623047 | Duke University | — |
| Completed | Study to Assess the Immune Response, the Safety and the Reactogenicity of Respiratory Syncytial Virus (RSV) Pr NCT05879107 | GlaxoSmithKline | Phase 3 |
| Completed | Evaluation of RSV/Flu-01E Vaccine for the Prevention of RSV Infection in Volunteers Aged 18 to 59 Years and Ov NCT05970744 | Tatyana Zubkova | Phase 1 |
| Active Not Recruiting | Safety and Immunogenicity of CodaVax-RSV in Seropositive and Seronegative Children NCT04919109 | Codagenix, Inc | Phase 1 |
| Recruiting | A Study of BLB-201 RSV Vaccine in Infants and Children NCT05655182 | Blue Lake Biotechnology Inc. | Phase 1 / Phase 2 |
| Completed | A Follow-up Study to Describe the Safety of Study Participants Who Received RSVPreF3 Maternal Vaccination (Any NCT05705440 | GlaxoSmithKline | Phase 3 |
| Unknown | The Epidemiology , Health and Economic Burden of RSV Amongst Hospitalized Children Under 5 Years of Age in Jor NCT05562817 | MENA Center for Research & Development and Internship | — |
| Completed | A Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus Given to Adults 50- NCT05590403 | GlaxoSmithKline | Phase 3 |
| Completed | A Study of TNM001 in Chinese Healthy Preterm and Term Infants NCT05630573 | Zhuhai Trinomab Pharmaceutical Co., Ltd. | Phase 1 / Phase 2 |
| Completed | A Study on the Immune Response and Safety Elicited by a Vaccine Against Respiratory Syncytial Virus (RSV) When NCT05559476 | GlaxoSmithKline | Phase 3 |
| Completed | A Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus (RSV) When Given Al NCT05568797 | GlaxoSmithKline | Phase 3 |
| Completed | A Dose Finding Study of VN-0200 NCT05547087 | Daiichi Sankyo | Phase 2 |
| Completed | Phase 1 Study of BLB-201 Vaccine in Healthy Young and Older Adults NCT05281263 | Blue Lake Biotechnology Inc. | Phase 1 |
| Completed | A Study to Learn About Effect of Sisunatovir in Healthy Adult Male Participants NCT05873764 | Pfizer | Phase 1 |
| Terminated | MVA-BN-RSV Vaccine Trial NCT05238025 | Bavarian Nordic | Phase 3 |
| Withdrawn | A Study of Safety, Reactogenicity and Immune Response of the Repeat Vaccination Against RSV When Given to Fema NCT05229068 | GlaxoSmithKline | Phase 3 |
| Recruiting | Azithromycin Treatment for Respiratory Syncytial Virus-induced Respiratory Failure in Children NCT05026749 | University of Alabama at Birmingham | Phase 3 |
| Completed | A Study to Evaluate the Safety and Immune Response to an Unadjuvanted RSV Maternal Vaccine in Healthy Non-preg NCT05169905 | GlaxoSmithKline | Phase 3 |
| Completed | Safety, Tolerability, Pharmacokinetics, and Food Effect Study of RV299 in Healthy Adults NCT06033612 | Pfizer | Phase 1 |
| Completed | A Phase III Study to Assess the Lot-to-lot Consistency of GSK's Investigational RSV Maternal Vaccine and the I NCT05045144 | GlaxoSmithKline | Phase 3 |
| Not Yet Recruiting | Epidemiology and Household Transmission of Streptococcus Pneumoniae and Respiratory Syncytial Virus NCT05017519 | Mackay Memorial Hospital | — |
| Completed | A Study of 3 Lots of an Investigational Vaccine Against Respiratory Syncytial Virus (RSV) in Adults Aged 60 Ye NCT05059301 | GlaxoSmithKline | Phase 3 |
| Terminated | A Study on the Safety and Immune Response to an Unadjuvanted RSV Maternal Vaccine, in High Risk Pregnant Women NCT04980391 | GlaxoSmithKline | Phase 3 |
| Terminated | Effects of EDP-938 in Hematopoietic Cell Transplant Recipients Infected With Respiratory Syncytial Virus of th NCT04633187 | Enanta Pharmaceuticals, Inc | Phase 2 |
| Completed | Study of VN-0200 in Japanese Healthy Adults and Elderly Subjects NCT04914520 | Daiichi Sankyo Co., Ltd. | Phase 1 |
| Completed | Efficacy Study of GSK's Investigational Respiratory Syncytial Virus (RSV) Vaccine in Adults Aged 60 Years and NCT04886596 | GlaxoSmithKline | Phase 3 |
| Completed | Safety and Efficacy of BARS13 in the Elderly NCT04681833 | Advaccine (Suzhou) Biopharmaceuticals Co., Ltd. | Phase 2 |
| Completed | A Study on the Immune Response and Safety Elicited by a Vaccine Against Respiratory Syncytial Virus (RSV) When NCT04841577 | GlaxoSmithKline | Phase 3 |
| Active Not Recruiting | Immunogenicity, Safety, Reactogenicity and Persistence of an Investigational Respiratory Syncytial Virus (RSV) NCT04732871 | GlaxoSmithKline | Phase 3 |
| Completed | A Study of XW001 in Healthy Adult Subjects NCT05642403 | Hangzhou Sciwind Biosciences Co., Ltd. | Phase 1 |
| Completed | Extension Study to Evaluate the Safety and Immunogenicity of a Revaccination Dose of the RSVPreF3 OA Investiga NCT04657198 | GlaxoSmithKline | Phase 2 |
| Terminated | A Phase III, Double-blind Study to Assess Safety and Efficacy of an RSV Maternal Unadjuvanted Vaccine, in Preg NCT04605159 | GlaxoSmithKline | Phase 3 |
| Completed | Study of RSVpreF Vaccination and RSV Challenge in Healthy Adults NCT04785612 | Hvivo | Phase 2 |
| Completed | A Study of AK0529 in Chinese Infants Hospitalized With RSV NCT04231968 | Shanghai Ark Biopharmaceutical Co., Ltd. | Phase 3 |
| Completed | Safety and Immunogenicity of a Live-attenuated Vaccine Against Respiratory Syncytial Virus in Elderly Voluntee NCT04295070 | Codagenix, Inc | Phase 1 |
| Completed | Study of the Safety and Immunogenicity of an Intranasal Vaccine for Respiratory Syncytial Virus in Seropositiv NCT04444284 | Meissa Vaccines, Inc. | Phase 1 |
| Terminated | Evaluation of a Single Use Point of Care Device for the Diagnosis of Respiratory Pathogens NCT04431050 | Imperial College London | — |
| Unknown | Evaluation of Performance of the LumiraDx Influenza A/B + RSV Test at POC Testing Sites NCT04288921 | LumiraDx UK Limited | N/A |
| Completed | Safety and Immune Response to an Investigational Vaccine Against Respiratory Syncytial Virus in Healthy Adults NCT04227210 | Meissa Vaccines, Inc. | Phase 1 |
| Terminated | Effects of JNJ-53718678 in Adult and Adolescent Participants Who Had a Hematopoietic Stem Cell Transplantation NCT04056611 | Janssen Sciences Ireland UC | Phase 2 |
| Completed | A Study of a Vaccine Against Respiratory Syncytial Virus (RSV) When Given Alone and Together With a Vaccine Ag NCT04138056 | GlaxoSmithKline | Phase 2 |
| Completed | Study of Safety, Reactogenicity and Immunogenicity of GlaxoSmithKline's (GSK)Respiratory Syncytial Virus (RSV) NCT04126213 | GlaxoSmithKline | Phase 2 |
| Unknown | Predictors of Respiratory Syncytial Virus (RSV) Hospitalizations in Infants NCT04144816 | Hospices Civils de Lyon | — |
| Completed | A Study to Test GlaxoSmithKline's (GSK) Respiratory Syncytial Virus RSV Candidate Vaccine's Safety and Immune NCT04090658 | GlaxoSmithKline | Phase 1 |
| Completed | Pharmacokinetics and Safety of RV521 Formulations NCT04065698 | Pfizer | Phase 1 |
| Completed | A Study to Evaluate the Safety of MEDI8897 for the Prevention of Medically Attended Respiratory Syncytial Viru NCT03959488 | AstraZeneca | Phase 2 / Phase 3 |
| Completed | A Study to Evaluate the Safety and Efficacy of MEDI8897 for the Prevention of Medically Attended Lower Respira NCT03979313 | AstraZeneca | Phase 3 |
| Completed | A Study of Outcomes and Events of Interest in Pregnant Women, Neonates and Infants and of RSV Surveillance NCT03614676 | GlaxoSmithKline | N/A |
| Completed | Respiratory Syncytial Virus (RSV) Investigational Vaccine in Infants Aged 6 and 7 Months Likely to be Unexpose NCT03636906 | GlaxoSmithKline | Phase 1 / Phase 2 |
| Unknown | Anti-RSV Study in Chinese Patients (ASCENT) NCT03699202 | Shanghai Ark Biopharmaceutical Co., Ltd. | Phase 2 |
| Completed | A Study to Assess the Safety, Reactogenicity and Immune Response of GlaxoSmithKline (GSK) Biologicals' Investi NCT03814590 | GlaxoSmithKline | Phase 1 / Phase 2 |
| Terminated | Study to Evaluate Safety and Antiviral Activity of Doses of JNJ-53718678 in Children (>=28 Days to <=3 Years) NCT03656510 | Janssen Research & Development, LLC | Phase 2 |
| Completed | A Study to Learn About the Drug-drug Interactions of Sisunatovir in Healthy Adult Participants NCT03782662 | Pfizer | Phase 1 |
| Terminated | Anti-viral Effect of PC786 on RSV Infection on HSCT Recipients NCT03715023 | Pulmocide Ltd | Phase 2 |
| Completed | A Study to Evaluate Different Dose Levels of GlaxoSmithKline (GSK) Biologicals' Investigational Respiratory Sy NCT03674177 | GlaxoSmithKline | Phase 1 |
| Completed | A First in Human Study to Evaluate the Safety and Immune Response to a Vaccine for the Treatment of a Respirat NCT04851977 | Advaccine (Suzhou) Biopharmaceuticals Co., Ltd. | Phase 1 |
| Completed | Inpatient Challenge Study of rRSV A/Maryland/001/11, a Human Respiratory Syncytial Virus Challenge Strain, Adm NCT03624790 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 1 |
| Completed | Inflammatory Mediators Associated With Infection by Respiratory Syncytial Virus NCT03757429 | Uppsala University | — |
| Completed | A Study to Explore the Antiviral Activity, Clinical Outcomes, Safety, Tolerability, and Pharmacokinetics of JN NCT03379675 | Janssen Research & Development, LLC | Phase 2 |
| Completed | Music Therapy With Intubated and Sedated Pediatric Patients NCT03629145 | Children's Healthcare of Atlanta | N/A |
| Completed | A Long-term Follow-up Study to Evaluate the Impact of Lumicitabine on the Incidence of Asthma and/or Wheezing NCT03332459 | Janssen Research & Development, LLC | Phase 2 |
| Completed | A Study of PC786 to Evaluate the Antiviral Activity, Safety and Pharmacokinetics of Multiple Doses in an RSV C NCT03382431 | Pulmocide Ltd | Phase 1 / Phase 2 |
| Completed | Evaluating the Infectivity, Safety, and Immunogenicity of Recombinant Live-Attenuated RSV Vaccines RSV ΔNS2/Δ1 NCT03227029 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 1 |
| Active Not Recruiting | RESCEU: Defining the Burden of RSV Disease NCT03698084 | University of Oxford | — |
| Unknown | RESCEU Study, Defining the Burden of Disease of RSV in Older Adults NCT03621930 | UMC Utrecht | — |
| Unknown | RESCEU Study: Defining the Burden of Disease of Respiratory Syncytial Virus in Europe in Infants NCT03627572 | UMC Utrecht | — |
| Completed | A Study to Learn About the Effects of Multiple Doses of Sisunatovir on People With Respiratory Syncytial Virus NCT03258502 | Pfizer | Phase 2 |
| Withdrawn | A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of the GlaxoSmithKline (GSK) Biologicals' Re NCT03191383 | GlaxoSmithKline | Phase 2 |
| Completed | A Study to Assess Safety, Tolerability and Immunogenicity of the Live Attenuated hRSV Vaccine rBCG-N-hRSV NCT03213405 | Pontificia Universidad Catolica de Chile | Phase 1 |
| Completed | Evaluating the Infectivity, Safety, and Immunogenicity of a Single Dose of a Recombinant Live-Attenuated Respi NCT03102034 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 1 |
| Completed | RSV Antibiotic Drivers And Resource-use NCT06977971 | Dr. Behcet Uz Children's Hospital | — |
| Completed | A Study to Evaluate Safety, Reactogenicity and Immunogenicity of GSK Biologicals' RSV Investigational Vaccine NCT02927873 | GlaxoSmithKline | Phase 1 / Phase 2 |
| Completed | A Study to Rank Different Dosages of Antigen of GlaxoSmithKline (GSK) Biologicals' Investigational Respiratory NCT02956837 | GlaxoSmithKline | Phase 2 |
| Completed | A Study to Evaluate the Safety and Efficacy of MEDI8897 for the Prevention of Medically Attended RSV LRTI in H NCT02878330 | MedImmune LLC | Phase 2 |
| Terminated | Evaluating the Infectivity, Safety and Immunogenicity of a Recombinant Live-Attenuated Respiratory Syncytial V NCT02890381 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 1 |
| Withdrawn | RSV-MVA-BN Vaccine Phase I Trial, Intranasal Application in Adults. NCT02864628 | Bavarian Nordic | Phase 1 |
| Completed | RSV-MVA-BN Vaccine Phase II Trial in ≥ 55 Year Old Adults NCT02873286 | Bavarian Nordic | Phase 2 |
| Completed | Specific Respiratory Infections as Triggers of Acute Medical Events NCT02984280 | University College, London | — |
| Terminated | Infectivity, Safety and Immunogenicity of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine (R NCT02948127 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 1 |
| Completed | Evaluating the Infectivity, Safety, and Immunogenicity of a Recombinant Live-Attenuated Respiratory Syncytial NCT02952339 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 1 |
| Completed | Evaluating the Infectivity, Safety and Immunogenicity of a Recombinant Live-Attenuated Respiratory Syncytial V NCT02794870 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 1 |
| Completed | Viral Inhibition in Children for Treatment of RSV NCT02654171 | Shanghai Ark Biopharmaceutical Co., Ltd. | Phase 2 |
| Completed | Safety and Reactogenicity Study of GlaxoSmithKline (GSK) Biologicals' Investigational Respiratory Syncytial Vi NCT02753413 | GlaxoSmithKline | Phase 2 |
| Completed | A Phase 2a Study to Evaluate Orally Administered ALS-008176 in Adults Hospitalized With a Respiratory Syncytia NCT02673476 | Alios Biopharma Inc. | Phase 2 |
| Terminated | A Study to Assess the Pharmacokinetics, Safety, and Tolerability of Multiple Doses of Orally Administered JNJ- NCT02593851 | Janssen Sciences Ireland UC | Phase 1 |
| Completed | A Study to Determine the Safety and Efficacy of the RSV F Vaccine to Protect Infants Via Maternal Immunization NCT02624947 | Novavax | Phase 3 |
| Completed | Idylla IFV-RSV Panel Clinical Testing NCT02786381 | Janssen Pharmaceutica N.V., Belgium | — |
| Completed | Safety and Immunogenicity of the RSV D46cpΔM2-2 Vaccine in RSV-Seropositive Children and RSV-Seronegative Infa NCT02601612 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 1 |
| Terminated | A Study of AK0529 in Infants Hospitalized With RSV NCT02460016 | Shanghai Ark Biopharmaceutical Co., Ltd. | Phase 1 |
| Completed | Trial to Evaluate the Safety, Tolerability and Immunogenicity of the Recombinant MVA BN® RSV Vaccine NCT02419391 | Bavarian Nordic | Phase 1 |
| Completed | Study to Evaluate the Efficacy and Safety of Suptavumab (REGN2222) for the Prevention of Medically Attended RS NCT02325791 | Regeneron Pharmaceuticals | Phase 3 |
| Completed | Study to Evaluate Antiviral Activity, Safety, and Pharmacokinetics of Repeated Doses of Orally Administered JN NCT02387606 | Janssen Sciences Ireland UC | Phase 2 |
| Completed | A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of ALS-008176 in Healthy Japanese Adult NCT02478333 | Janssen Pharmaceutical K.K. | Phase 1 |
| Completed | Safety, Reactogenicity and Immunogenicity Study of Different Formulations of GlaxoSmithKline (GSK) Biologicals NCT02360475 | GlaxoSmithKline | Phase 2 |
| Completed | Safety, Tolerability and PK Study of AK0529 in Healthy Human NCT02297594 | Shanghai Ark Biopharmaceutical Co., Ltd. | Phase 1 |
| Completed | RSV F Vaccine Maternal Immunization Study in Healthy Third-trimester Pregnant Women. NCT02247726 | Novavax | Phase 2 |
| Completed | Safety and Immune Response to a Live-Attenuated Respiratory Syncytial Virus (RSV) Vaccine in RSV-Seronegative NCT02237209 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 1 |
| Completed | Safety and Immune Response to a Live-Attenuated Respiratory Syncytial Virus (RSV) Vaccine in RSV-Seronegative NCT02040831 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 1 |
| Completed | A Phase 1, Open-Label Study of the Absorption, Metabolism, Excretion and Absolute Bioavailability of ALS-00817 NCT02231671 | Alios Biopharma Inc. | Phase 1 |
| Completed | A Study of ALS-008176 in Infants Hospitalized With RSV NCT02202356 | Alios Biopharma Inc. | Phase 1 |
| Completed | A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI8897 in Healthy Adults NCT02114268 | MedImmune LLC | Phase 1 |
| Completed | A Phase 2a Study to Evaluate ALS-008176 in the Virus Challenge Model NCT02094365 | Alios Biopharma Inc. | Phase 2 |
| Completed | Evaluating the Safety and Immune Response to a Single Dose of a Respiratory Syncytial Virus (RSV) Vaccine in R NCT01968083 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 1 |
| Completed | Evaluating the Safety and Immune Response to a Single Dose of a Respiratory Syncytial Virus (RSV) Vaccine in R NCT01852266 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 1 |
| Unknown | Infection With Respiratory Syncytial Virus in Infants NCT04925310 | Hannover Medical School | — |
| Completed | RSV F Dose-Ranging Study in Women NCT01960686 | Novavax | Phase 2 |
| Completed | Respiratory Syncytial Virus Infection in Neonatal Intensive Care Units Throughout Turkey: Prospective Multicen NCT01915394 | Ankara University | — |
| Completed | RSV Observational Study 2 NCT01922648 | University of Oxford | — |
| Unknown | Evaluating the Safety and Immune Response to a Single Dose of a Respiratory Syncytial Virus (RSV) Vaccine in I NCT01893554 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 1 |
| Completed | Study of Single and Multiple Doses of ALS-008176 in Healthy Volunteers NCT01906164 | Alios Biopharma Inc. | Phase 1 |
| Withdrawn | Safety Study of GS-5806 to Treat Respiratory Syncytial Virus (RSV) NCT01797419 | Gilead Sciences | Phase 1 |
| Completed | RSV001 - A New Vaccine to Prevent Severe Viral Chest Infections. NCT01805921 | ReiThera Srl | Phase 1 |
| Completed | Surveillance Study of Respiratory Syncytial Virus Infection (RSV) in Subjects < 24 Months of Age NCT01754428 | Gilead Sciences | — |
| Completed | Safety and Efficacy Study of GS-5806 in Healthy Volunteers Infected With Respiratory Syncytial Virus (RSV) NCT01756482 | Gilead Sciences | Phase 2 |
| Completed | Cell Mediated Immunity Against RSV and Influenza in a Human Experimental Challenge NCT02755948 | Imperial College London | N/A |
| Completed | Respiratory Syncytial Virus - RSV Protocol NCT01502072 | M.D. Anderson Cancer Center | Phase 2 |
| Completed | A Trial to Assess the Safety, Tolerability, and Pharmacokinetics of MDT-637 in Healthy Volunteers NCT01355016 | MicroDose Therapeutx, Inc | Phase 1 |
| Completed | Evaluating the Safety and Immune Response to a Respiratory Syncytial Virus (RSV) Vaccine in Adults, RSV-Seropo NCT01459198 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 1 |
| Completed | The Development of a Human Model of Respiratory Syncytial Virus Infection NCT01349543 | Imperial College London | N/A |
| Completed | Collection and Testing of Respiratory Samples NCT01302418 | QIAGEN Gaithersburg, Inc | — |
| Completed | Safety Study of Respiratory Syncytial Virus (RSV)-Fusion (F) Protein Particle Vaccine NCT01290419 | Novavax | Phase 1 |
| Completed | RV568 - Viral Challenge With RSV NCT01230645 | Respivert Ltd | Phase 1 |
| Completed | Phase 2b Study of ALN-RSV01 in Lung Transplant Patients Infected With Respiratory Syncytial Virus (RSV) NCT01065935 | Alnylam Pharmaceuticals | Phase 2 |
| Completed | Phase 2 Study of ALN-RSV01 in Lung Transplant Patients Infected With Respiratory Syncytial Virus (RSV) NCT00658086 | Alnylam Pharmaceuticals | Phase 2 |
| Completed | Association Between Cytokines and Severity of Respiratory Syncytial Virus (RSV)-Induced Illness in the Elderly NCT00609635 | West Penn Allegheny Health System | — |
| Completed | Safety Study of Oral BTA9881 to Treat RSV Infection NCT00504907 | Biota Scientific Management Pty Ltd | Phase 1 |
| Completed | Intranasal ALN-RSV01 Administered to Adult Volunteers Experimentally Inoculated With Respiratory Syncytial Vir NCT00496821 | Alnylam Pharmaceuticals | Phase 2 |
| Completed | Safety and Tolerability Study to Evaluate MEDI-534 in Children 6 to < 24 Months of Age NCT00493285 | MedImmune LLC | Phase 1 |
| Completed | Study to Evaluate the Incidence of Hospitalizations and Respiratory Tract Infections in Premature Infants NCT00384462 | MedImmune LLC | — |
| Completed | Study of Motavizumab (MEDI-524) and Palivizumab Administered Sequentially in the Same Respiratory Syncytial Vi NCT00316264 | MedImmune LLC | Phase 2 |
| Completed | Utilization and Compliance of Respiratory Syncytial Virus Monoclonal Antibody Therapy NCT00420966 | Sunnybrook Health Sciences Centre | — |
| Completed | A Study of the Safety and Efficacy of A-60444 in Adults With Respiratory Syncytial Virus (RSV) Infection Follo NCT00232635 | Arrow Therapeutics | Phase 2 |
| Completed | Study to Evaluate MEDI-534 in Healthy Adults NCT00111878 | MedImmune LLC | — |
| Unknown | Continuous Exhaled Breath Condensate pH in Mechanically Ventilated Patients NCT00429637 | University of Virginia | — |
| Completed | Study of MEDI-524 (Motavizumab) for the Prophylaxis of Serious Respiratory Syncytial Virus (RSV) Disease in Hi NCT00129766 | MedImmune LLC | Phase 3 |
| Completed | Open-Label, Dose-Escalation Study of 2 to 5 IM Doses of MEDI-524 at 3 mg/kg or 15 mg/kg; Children to be Follow NCT00192478 | MedImmune LLC | Phase 1 / Phase 2 |
| Completed | Assessment of Airway Obstruction in Infants With Lower Respiratory Infections NCT00435994 | Indiana University School of Medicine | N/A |
| Completed | Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI-524 in Healthy Adults NCT00192465 | MedImmune LLC | Phase 1 |
| Completed | Prospective Study for the Use of Palivizumab (Synagis®) in High-risk Children in Germany NCT01155193 | AbbVie (prior sponsor, Abbott) | — |
| Terminated | Ribavirin to Prevent RSV Pneumonia in Bone Marrow Transplant Patients NCT00031473 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 3 |